1. Henry N. Ginsberg, MD

    • Department of Medicine
      Division of Preventive Medicine
    Headshot

    Honors and Awards

    • Alpha Omega Alpha
    • 1981-1986 Public Health Service Research Career Development Award
    • 1981-1986 Irma T. Hirschl Career Scientist Award
    • 1984 Irvine H. Page Award: American Heart Association - Honorable Mention
    • 1986 American Society for Clinical Investigation
    • 1992 Mary Rose Swartz Invited Lectureship of the New York Dietetic Association
    • 1996 American Association of Physicians
    • 1996 David Rubenstein Lecture of the Canadian Lipid Club
    • 1997 Albert Hogan Memorial Lecture, University of Missouri
    • American Heart Association Special Recognition Award
    CUMC crown logoHenry N. Ginsberg, MD
    is accepting new patients.
    Call (212) 305-9562 for appointments.

    Provider Information

    Board Certifications

    • Preventive Medicine
    • Internal Medicine
    • Endocrinology, Diabetes and Metabolism

    Clinical Expertise

    • Cholesterol Management

    Hospital Affiliations

    • NewYork-Presbyterian/Columbia

    Primary Location

    • Presbyterian Hospital and Vanderbilt Clinic

      622 West 168th Street
      Floor: PH10, Room: 307
      New York, NY 10032
      For new and current patient appointments, call:
      (212) 305-9562
      Fax:
      (212) 305-3213

    Insurance Programs

    Please contact the provider’s office directly to verify that your particular insurance is accepted.
    • Aetna [EPO, HMO, Medicare, NY Signature, POS, PPO, Signature Administrators, Student Health]
    • Affinity [Access (Exchange), Essential Plan, Medicaid Managed Care, Medicare Managed Care]
    • Amida Care
    • Cigna [EPO, Great West, HMO, POS, PPO]
    • Emblem/HIP [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]
    • Empire Blue Cross Blue Shield [Blue Priority, EPO, HMO, Medicare (Mediblue), NYP Employee Plan, Pathway (Exchange), POS, PPO]
    • Empire Blue Cross Blue Shield HealthPlus [Child/Family Health Plus, Essential Plan, Medicaid Managed Care]
    • Fidelis Care [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]
    • Healthfirst [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]
    • Local 1199
    • MagnaCare
    • Medicare [Medicare]
    • Oxford Health Plans [Freedom, Liberty, Medicare Managed Care]
    • POMCO
    • UnitedHealthcare [Columbia University Employee Plan, Compass (Exchange), EPO, HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]
    • VNSNY CHOICE [SelectHealth]

    Biographical Detail

    Academic Appointments

    • Herbert and Florence Irving Professor of Medicine

    Current Administrative Positions

    • Director, Irving Institute for Clinical & Translational Research

    Education And Training

      Education & Training

    • State University of New York - Downstate Health Sciences Center
    • Internship: Boston City Hospital
    • Residency: Boston City Hospital
    • Fellowship: Stanford University Medical Center

    Gender

    Male

    Languages Spoken

    • Spanish
  2. Dr. Ginsberg conducts research related to the regulation of the levels and metabolism of apolipoprotein B-containing lipoproteins, the lipoproteins carrying triglycerides and the bulk of cholesterol in blood. These include the atherogenic very low density and low density lipoproteins.

    Dr. Ginsberg has a particular emphasis on the pathophysiology of hypertriglyceridemia and the dyslipidemia associated with insulin resistance and diabetes mellitus. Research is conducted at three levels: tissue culture using both human and rat hepatoma cells, transgenic mice, and human clinical studies. In cultured cells, Dr. Ginsberg and his associates have described the role of lipid substrate availability in determining if newly synthesized a of degradation and lipoprotein assembly of apoB. His group has characterized the role of the proteasome in the degradation of apoB. In transgenic mice, he had developed a model of insulin resistance and dylipidemia with many characteristics of the human disorder. This model, as well as others now in use in the lab, allow the group to dissect the important components of substrate availability and genetic control that lead to hypertriglyceridemia. Dr. Ginsberg's group makes and studies transgenic mice, conducting whole body, cellular, and molecular experiments.

    In clinical studies, Dr. Ginsberg is investigating postprandial hyperlipidemia as a risk factor in patients with diabetes. He is also part of a group at Columbia that will be studying the role of glycemic, lipid and blood pressure control in the prevention of cardiovascular disease in patients with diabetes. The latter, named the ACCORD trial, is a 10-year trial with 10,000 patients at 6 sites across the United States. Dr. Ginsberg also has a long record of research into the effects of diet on lipid and lipoprotein metabolism in humans, and has conducted numerous controlled feeding studies in humans.

    Research Information

    Research Interests

    • Molecular and cellular regulation of hypertriglyceridemia, particularly in patients and animal models of insulin resistance and diabetes

    Grants/Contracts

    • HEPATIC WNT/LRP6 REGULATION OF PLASMA LIPIDS (Federal Gov)

      Nov 19 2014 - Oct 31 2019

      OPEN-LABEL EXTENSION STUDY OF EFC12492, R727-CL-1112, EFC12732, & LTS11717 STUDIES TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF ALIROCUMAB IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (P&S Industry Clinical Trial)

      Jun 5 2014 - Jun 5 2019

      MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY,TOLERABILITY, AND EFFICACY OF AMG 145 ON LDL-C IN SUBJECTS WITH SEVERE FAMILIAL HYPERCHOLESTEROLEMIA (P&S Industry Clinical Trial)

      May 13 2014 - May 13 2019

      A 2-PART, PHASE 2/3 STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF AMG 145 IN SUBJECTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PART A (P&S Industry Clinical Trial)

      Sep 12 2013 - Sep 12 2018

      POSTDOCTORAL TRAINING IN ARTERIOSCLEROSIS RESEARCH (Federal Gov)

      Jul 1 1978 - Jul 31 2018

      1-DAY HYPERTRIGLYCERIDEMIA MEDICAL PRECEPTORSHIP PROGRAM. (P&S Industry Clinical Trial)

      Jul 11 2013 - Jul 11 2018

      PROPOSAL TO VALIDATE THE USE OF 2H20 FOR STUDIES OF HUMAN LIPID AND APOLIPOPROTEIN METABOLISM." (P&S Industry Clinical Trial)

      Dec 6 2012 - Dec 6 2017

      A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED. PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAR236553/REGN727 IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA NOT ADEQUATELY CONTROLLED WITH THEIR LIPID-MODIFYING THERAPY (P&S Industry Clinical Trial)

      Nov 21 2012 - Nov 21 2017

      ASSEMBLY AND SECRETION OF APOB CONTAINING LIPOPROTEINS (Federal Gov)

      Jul 22 2013 - May 31 2017

      MIPO1600810 (P&S Industry Clinical Trial)

      Aug 23 2011 - Aug 23 2016

      CLINICAL AND TRANSLATIONAL SCIENCE AWARD (Federal Gov)

      Sep 30 2006 - Jun 30 2016

      CLINICAL AND TRANSLATIONAL SCIENCE AWARD (Federal Gov)

      Sep 30 2006 - Jun 30 2016

      CLINICAL AND TRANSLATIONAL SCIENCE AWARD (Federal Gov)

      Sep 30 2006 - Jun 30 2016

      CLINICAL AND TRANSLATIONAL SCIENCE AWARD (KL2) (Federal Gov)

      Sep 30 2006 - Jun 30 2016

      CLINICAL AND TRANSLATIONAL SCIENCE AWARD (TL1) (Federal Gov)

      Sep 30 2006 - Jun 30 2016

      PATHWAYS OF FENOFIBRATE EFFECTS ON CARDIOVASCULAR OUTCOMES IN ACCORD (Federal Gov)

      Apr 1 2012 - Mar 31 2016

      THE METABOLIC IMPACT OF CONGENITAL HETEROZYGOUS APOC-III DEFICIENCE IN HUMANS (Federal Gov)

      Jan 14 2011 - Dec 31 2015

      UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONA (Federal Gov)

      Sep 1 2014 - Jun 30 2015

      LIPOPROTEIN METABOLISM OF CETP INH. (P&S Industry Clinical Trial)

      Nov 2 2009 - Nov 2 2014

      A PHASE III,DOUBLE-BLIND,RANDOMIZED,PLACEBO-CONTROLLED STUDYTO EVALUATE THE EFFECTS OF DALCETRAPID ON CARDIOVASCULAR(CV) (P&S Industry Clinical Trial)

      Sep 15 2009 - Sep 15 2014

      ISIS 301012-CS6: AN OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG TERM SAFETY AND EFFICACY OF ISIS 301012 IN SUBJECTS WI (P&S Industry Clinical Trial)

      Sep 15 2009 - Sep 15 2014

      FATTY ACID REGULATION OF LIVER LIPOPROTEIN PRODUCTION (Federal Gov)

      Apr 1 2003 - Jun 30 2013

      RADICHOL II (P&S Industry Clinical Trial)

      Oct 14 2008 - Jun 30 2011

      CLINICAL AND TRANSLATIONAL SCIENCE AWARD (UL1) (Federal Gov)

      Sep 30 2006 - Jun 30 2011

      LIPOPROTEIN METABOLISM IN PATIENTS WITH TYPE 2 DIABETES MELLITUS-EFFECTS IF PIOGLITAZONE COMPARED WITH ROSIGLITAZONE (P&S Industry Clinical Trial)

      Dec 22 2004 - Jun 30 2009

      EFFECTS OF DIACYGLECEROL OIL VERSUS TRIACYGLYCEROL OIL INGESTION ON POSTPRANDIAL PLASMA TG RESPONSES (P&S Industry Clinical Trial)

      Apr 22 2004 - Jun 30 2009

      STUDY TO ASSESS THE EFFICACY AND SAFETY OF COMBINED OMACOR AND SIMVASTATIN THERAPY IN HYPERTRIGLYCERIDEMIC SUBJECTS (P&S Industry Clinical Trial)

      Feb 27 2006 - Aug 31 2008

  3. publications

    • Liang, J-s., Kim, T., Fang, S., Weissman, A.M., Fisher, E.A., and Ginsberg, H.N. (2003) Overexpression of the tumor autocrine motility factor receptor-gp78, a ubiquitin protein ligase (E3), results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in Hep G2 cells. J Biol Chem 278:23984-8
    • Ginsberg, H.N. and Fisher, E.A. (2002) Complexity in the secretory pathway: The assembly and secretion of apolipoprotein B-containing lipoproteins. J. Biol. Chem 277:17377-80
    • Siri P., Candela, N., Ko, C., Zhang Y., Eusufzai, S., Ginsberg, H.N., and Huang Li-Shin. (2001) Post-transcriptional stimulation of the assembly and secretion of triglyceride-rich apolipoproteinB-lipoproteins in a mouse with selective deficiency of brown adipose tissue, obesity and insulin resistance. J Biol Chem 276:46064-72
    • Liang, J-S., Distler, O., Cooper, D, Jamil, H., Deckelbaum, R.J., Ginsberg, H.N. and Sturley, S.J. (2001) HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia. Nature Medicine 7:1327-31
    • Mitchell, D.M., Zhou, M., Pariyarath, R. Wang, H., Aitchison, J.D. Ginsberg, H.N. and Fisher, E.A. (1998) Apoprotein B has a prolonged interaction with the translocon during which its lipidation and translocation changes from MTP-dependent to MTP-independent. Proc. Natl. Acad. Sci. USA. 95:14733-8
    • Zhou, M.Y., Fisher, E.A., Ginsberg, H.N. (1998) Regulatable co-translational ubiquitination of apolipoprotein B:100: A new paradigm for proteasomal degradation of a secretory protein. J. Biol. Chem. 38:24649-53

    For a complete list of publications, please visit PubMed.gov